INOMAX is an inhaled vasodilator |
INOMAX® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.
INOMAX Important Safety Information (ISI)
INOMAX should not be used in the treatment of neonates known to be dependent on right-to-left shunting of blood
Method of Administration
INOMAX MOAInhalation of INOMAX offers selective activity
- The only FDA-approved drug that selectively dilates the pulmonary vasculature8
- Targeted delivery to the pulmonary bed8
Inhalation of INOMAX offers rapid onset
- Clinical responses seen in as little as 30 minutes8
- INOMAX causes vasodilation in the pulmonary vasculature
Inhalation of INOMAX offers rapid clearance
- Rapid inactivation by hemoglobin minimizes systemic effects8,11
- Nitrate, the predominant metabolite of nitric oxide, is rapidly cleared by the kidneys8
Methemoglobinemia is a dose-dependent side effect of inhaled nitric oxide therapy. Therefore, methemoglobin levels should be monitored during INOMAX administration.
References
8. INOMAX® [package insert]. Hampton, NJ: Ikaria Holdings; 2010.
9. Golombek SG, Young JN. Efficacy of inhaled nitric oxide for hypoxic respiratory failure in term and late preterm infants by baseline severity of illness: a pooled analysis of three clinical trials. Clin Ther. 2010;32(5):939-948.
8. INOMAX® [package insert]. Hampton, NJ: Ikaria Holdings; 2010.
11. Steudel W, Hurford WE, Zapol WM. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology. 1999;91(4):1090-1121.
12. Davidson D, Barefield ES, Kattwinkel J, et al. Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. Pediatrics. 1998;101(3 Pt 1):325-334.